Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1308256-94-1

LHW090-A7 is a compound specifically designed to inhibit neutral endopeptidase (NEP), an enzyme that plays a crucial role in the metabolic inactivation of enkephalins. By blocking the action of NEP, LHW090-A7 has the potential to elevate the levels of endogenous atrial natriuretic peptides in the plasma, which can lead to natriuretic and diuretic effects.

1308256-94-1 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

  • (2S)-3-{3'-chloro-[1,1'-biphenyl]-4-yl}-2-{[(2S)-1-ethoxy-1-oxopropan-2-yl]amino}propanoic acid

    Cas No: 1308256-94-1

  • USD $ 1.9-2.9 / Gram

  • 100 Gram

  • 1000 Metric Ton/Month

  • Chemlyte Solutions
  • Contact Supplier
  • 1308256-94-1 Structure

  • Basic information

    1. Product Name: LHW090-A7
    2. Synonyms: LHW090-A7;(S)-3-(3'-Chloro-[1,1'-biphenyl]-4-yl)-2-(((S)-1-ethoxy-1-oxopropan-2-yl)amino)propanoic acid;Sodium (2S)-3-(3'-chloro-[1,1'-biphenyl]-4-yl)-2-{[(2S)-1-ethoxy-1-oxopropan-2-yl]amino}propanoate;(alphaS)-3'-Chloro-alpha-[[(1S)-2-ethoxy-1-methyl-2-oxoethyl]amino][1,1'-biphenyl]-4-propanoic acid;EOS-61103
    3. CAS NO:1308256-94-1
    4. Molecular Formula: C20H22ClNO4
    5. Molecular Weight: 375.84598
    6. EINECS: -0
    7. Product Categories: N/A
    8. Mol File: 1308256-94-1.mol

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: LHW090-A7(CAS DataBase Reference)
    10. NIST Chemistry Reference: LHW090-A7(1308256-94-1)
    11. EPA Substance Registry System: LHW090-A7(1308256-94-1)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 1308256-94-1(Hazardous Substances Data)

1308256-94-1 Usage

Uses

Used in Pharmaceutical Industry:
LHW090-A7 is used as a therapeutic agent for the treatment of conditions related to fluid and electrolyte imbalances. By inhibiting NEP, it can increase the levels of atrial natriuretic peptides, which in turn promotes natriuresis and diuresis, helping to regulate fluid balance in the body.
Additionally, due to its mechanism of action, LHW090-A7 may also be used as a research tool to study the role of NEP in various physiological processes and its potential involvement in other conditions, such as hypertension and heart failure.

Check Digit Verification of cas no

The CAS Registry Mumber 1308256-94-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,0,8,2,5 and 6 respectively; the second part has 2 digits, 9 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1308256-94:
(9*1)+(8*3)+(7*0)+(6*8)+(5*2)+(4*5)+(3*6)+(2*9)+(1*4)=151
151 % 10 = 1
So 1308256-94-1 is a valid CAS Registry Number.

1308256-94-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name (S)-3-(3'-chlorobiphenyl-4-yl)-2-((S)-1-ethoxycarbonylethylamino)propionic acid

1.2 Other means of identification

Product number -
Other names (S)-3-(3'-chloro-biphenyl-4-yl)-2-((S)-1-ethoxycarbonyl-ethylamino)-propionic acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1308256-94-1 SDS

1308256-94-1Relevant articles and documents

METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY

-

Paragraph 0584, (2016/08/23)

The present invention provides the use of a neutral endopeptidase inhibitor, in the manufacture of a medicament for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The invention also relates to the use of a compound of Formula I: wherein R1, R2, R3, R5, X, A3, B1, s and n are defined herein, for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of contrast-induced nephropathy.

METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY

-

, (2012/05/21)

The present invention provides the use of a neutral endopeptidase inhibitor, in the manufacture of a medicament for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The invention also relates to the use of a compound of Formula I: wherein R1, R2, R3, R5, X, A3, B1, s and n are defined herein, for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of contrast-induced nephropathy.

Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors

-

Page/Page column 41-42, (2011/06/19)

The present invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R6, A1, A2, X1, s and m are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1308256-94-1